• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Exscientia Ltd ADR (NQ: EXAI )

    5.110 -0.260 (-4.84%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 24, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 338,161
    Open 5.470
    Bid (Size) 5.070 (15)
    Ask (Size) 5.620 (9)
    Prev. Close 5.370
    Today's Range 5.020 - 5.520
    52wk Range 3.860 - 9.100
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD
    To capitalize on the transition to more AI-focused drug development investors need to understand the drug development process and the financial health and market potential of those companies under... 
    Via Talk Markets
    Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout
    From Exscientia plc
    Via Business Wire

    Performance

    YTD
    -18.31%
    -18.31%
    1 Month
    -2.48%
    -2.48%
    3 Month
    +16.67%
    +16.67%
    6 Month
    -16.37%
    -16.37%
    1 Year
    -33.12%
    -33.12%

    More News

    Read More
    Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
    Via Talk Markets
    Exscientia Launches AWS AI-powered Platform to Advance Drug Discovery
    From Exscientia plc
    Via Business Wire
    3 Small-Cap Stocks With Explosive 2X Growth Potential
    Via InvestorPlace
    Clinical-Stage BioTech Drug Stocks Declined 13% In June
    Via Talk Markets
    EXAI Investors Have Opportunity to Lead Exscientia plc Securities Fraud Lawsuit with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Exscientia p.l.c. (EXAI)
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    EXAI FINAL DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Exscientia p.l.c. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – EXAI
    From The Rosen Law Firm PA
    Via GlobeNewswire
    EXAI Investors Have Opportunity to Lead Exscientia plc Securities Fraud Lawsuit with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    Largest Clinical-Stage BioTech Drug Stocks Declined 6%
    Via Talk Markets
    EXSCIENTIA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Exscientia plc. and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Exscientia
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    Lowey Dannenberg Notifies Exscientia p.l.c. (“Exscientia” or the “Company”) (NASDAQ: EXAI) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm
    From Lowey Dannenberg, P.C.
    Via GlobeNewswire
    EXAI Investors Have Opportunity to Lead Exscientia plc Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    EXSCIENTIA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Exscientia p.l.c. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – EXAI
    From The Rosen Law Firm PA
    Via GlobeNewswire
    EXAI Investors Have Opportunity to Lead Exscientia plc Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GoodRx, Exscientia, Malibu Boats, and Equinix and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    AI-Focused Drug Discovery Stocks Portfolio Down 4% W/e June 14th
    Via Talk Markets
    Lowey Dannenberg Notifies Exscientia p.l.c. (“Exscientia” or the “Company”) (NASDAQ: EXAI) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm
    From Lowey Dannenberg, P.C.
    Via GlobeNewswire
    EXSCIENTIA PLC (NASDAQ: EXAI) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Exscientia plc
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    Rosen Law Firm Urges Exscientia p.l.c. (EXAI) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
    From The Rosen Law Firm, P.A.
    Via Business Wire
    Lowey Dannenberg Notifies Exscientia p.l.c. (“Exscientia” or the “Company”) (NASDAQ: EXAI) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm
    From Lowey Dannenberg, P.C.
    Via GlobeNewswire
    ROSEN, A LEADING LAW FIRM, Encourages Exscientia p.l.c Investors to Secure Counsel Before Important Deadline in Securities Class Action – EXAI
    From The Rosen Law Firm PA
    Via GlobeNewswire
    INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Exscientia
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.